GLP-1 Semaglutide (2 x 10mg vials)

GLP-1 Semaglutide

Product Format	10mg vials
Vial Size	10mg
Vial Capacity	3 mL
Box Combinations	50mg, 100mg, 150mg, 200mg
Cost per milligram	$4.88 – $5.70
Multi-vial Purity	99.82%
Endotoxin Screening	PASSED
Heavy Metals Screening	PASSED
Purity Screening	PASSED
Doubly Validated	YES
Independently Tested	YES

• Peptide Partners Manufacturer ID: VI32
• Batch Id: SM202607

 

Research Studies

(for educational purposes only)

 

Study 1: Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

Authors: Yawei Tian, Huiming Liu, Xiaoxue Bao, Yukun Li

Source: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1539411/full

Scientific Findings

This in vitro study investigated the effects of semaglutide on bone-derived mesenchymal stem cells (BMSCs). The results demonstrated that semaglutide promotes BMSC proliferation and osteogenic differentiation. This was evidenced by increased alkaline phosphatase (ALP) activity, enhanced mineralization, and upregulation of osteogenic markers such as osteocalcin (OCN) and Runt-related transcription factor 2 (RUNX2). RNA sequencing analysis revealed the activation of the Wnt/LRP5/β-catenin signaling pathway. The study confirmed that semaglutide’s pro-osteogenic effects are mediated through this pathway by using a Wnt inhibitor (DKK1) and activator (LiCl).

Plain English Interpretation

This laboratory study explored how the drug semaglutide affects stem cells taken from bone marrow. The researchers found that semaglutide encourages these stem cells to multiply and transform into bone-forming cells. This was observed through various experiments that showed an increase in the activity of enzymes and proteins essential for bone formation. The study identified a specific communication pathway within the cells, known as the Wnt pathway, which is activated by semaglutide to produce these bone-strengthening effects. This suggests that semaglutide could have potential benefits for bone health by promoting the generation of new bone tissue.

 

Study 2: The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance

Authors: Emmalie R. Spry, Kipton B. Travis, Kayla J. Ragland, Alexa J. Klein, John M. Zimmerman, Roger A. Vaughan

Source: https://www.sciencedirect.com/science/article/abs/pii/S0303720725001807

Scientific Findings

This study investigated the effects of semaglutide on C2C12 myotubes in an in vitro model of insulin resistance. The researchers found that while semaglutide did not alter insulin sensitivity, as measured by pAkt:Akt ratio, it did significantly increase the expression of genes associated with mitochondrial biogenesis and function, including PGC-1α, and TFAM. Furthermore, semaglutide treatment led to an increase in mitochondrial content and density, as well as an increase in maximal mitochondrial respiration. These findings suggest that semaglutide may improve metabolic health by enhancing mitochondrial function in skeletal muscle, independent of its effects on insulin signaling.

Plain English Interpretation

In this lab experiment, scientists looked at how the drug semaglutide affects muscle cells that have been made resistant to insulin, similar to what happens in type 2 diabetes. They discovered that while semaglutide didn’t make the cells more responsive to insulin, it did boost the number and activity of mitochondria, which are the ‘powerhouses’ of the cells. This means that semaglutide might help improve metabolism by making muscle cells better at producing energy, even if it doesn’t directly fix the insulin resistance problem.

 

Study 3: Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis

Authors: Yan-fang Chang, Di Zhang, Wei-min Hu, Dong-xing Liu, Lin Li

Source: https://www.sciencedirect.com/science/article/abs/pii/S0967586820315332

Scientific Findings

This in vitro study investigated the neuroprotective effects of semaglutide in a SH-SY5Y cell line model of Alzheimer’s disease, induced by amyloid-β 25-35 (Aβ25-35). The results showed that semaglutide treatment restored cell viability that was inhibited by Aβ25-35. Mechanistically, semaglutide was found to enhance autophagy, as indicated by increased expression of autophagy-related proteins such as LC3-II, Atg7, and Beclin-1, and decreased expression of p62. Furthermore, semaglutide inhibited apoptosis by increasing the Bcl-2/Bax ratio. These findings suggest that semaglutide protects against Aβ-induced neurotoxicity by promoting autophagy and suppressing apoptosis.

Plain English Interpretation

In this laboratory study, scientists used a cell model to mimic the effects of Alzheimer’s disease on brain cells. They found that the drug semaglutide could protect these cells from damage. Semaglutide appeared to work in two main ways: first, it boosted the cells’ natural ‘recycling’ process, called autophagy, which helps clear out harmful substances. Second, it prevented the cells from self-destructing, a process known as apoptosis. This research suggests that semaglutide could have a protective effect on brain cells, which might be relevant for neurodegenerative diseases like Alzheimer’s.

Related Products

• 5-Amino-1MQ (2 x 10mg vials)
• GLP-1 Semaglutide (20 x 10mg vials)
• GLP-1 Semaglutide (15 x 10mg vials)

Browse more in Metabolics.